Shares of IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) saw unusually-strong trading volume on Wednesday . Approximately 9,864,656 shares were traded during trading, an increase of 690% from the previous session’s volume of 1,248,599 shares.The stock last traded at $0.38 and had previously closed at $0.33.
Several equities analysts have commented on IPCI shares. ValuEngine upgraded shares of IntelliPharmaCeutics Intl from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Maxim Group set a $6.00 target price on shares of IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a report on Thursday, December 20th.
An institutional investor recently bought a new position in IntelliPharmaCeutics Intl stock. Geode Capital Management LLC bought a new position in IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 180,877 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.93% of IntelliPharmaCeutics Intl at the end of the most recent quarter. Institutional investors own 4.57% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “IntelliPharmaCeutics Intl (IPCI) Sees Strong Trading Volume” was originally posted by Zolmax and is the property of of Zolmax. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://zolmax.com/investing/intellipharmaceutics-intl-ipci-sees-strong-trading-volume/2914967.html.
IntelliPharmaCeutics Intl Company Profile (NASDAQ:IPCI)
IntelliPharmaCeutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
Further Reading: How prevalent are 12b-1 fees?
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.